Human Vγ9Vδ2 T cell expansion and their cytotoxic responses against cholangiocarcinoma.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
14 Jan 2024
14 Jan 2024
Historique:
received:
13
02
2023
accepted:
09
01
2024
medline:
15
1
2024
pubmed:
15
1
2024
entrez:
14
1
2024
Statut:
epublish
Résumé
Human Vγ9Vδ2 T lymphocytes are regarded as promising effector cells for cancer immunotherapy since they have the ability to eliminate several tumor cells through non-peptide antigen recognition. However, the cytotoxic function and the mechanism of Vγ9Vδ2 T cells leading to specific killing of cholangiocarcinoma cells are yet to be confirmed. In this study, we established a protocol for ex vivo expansion of Vγ9Vδ2 T cells from healthy donors' peripheral blood mononuclear cells by culture with zoledronate and addition of IL-2, and IL-15 or IL-18 or neither. Testing the cytotoxic capacity of cultured Vγ9Vδ2 T cells against cholangiocarcinoma cell lines showed higher reactivity than against control cells. Surface expression of CD107 was detected on the Vγ9Vδ2 T cells, suggesting that these cells limit in vitro growth of cholangiocarcinoma cells via degranulation of the perforin and granzyme pathway. Analysis of molecular signaling was used to demonstrate expression of pro- and anti-survival genes and a panel of cytokine genes in Vγ9Vδ2 T cells. We found that in the presence of either IL-15 or IL-18, levels of caspase 3 were significantly reduced. Also, IL-15 and IL-18 stimulated cells contained cytotoxicity against cholangiocarcinoma cells, suggesting that stimulated Vγ9Vδ2 T cells may provide a feasible therapy for cholangiocarcinoma.
Identifiants
pubmed: 38221530
doi: 10.1038/s41598-024-51794-1
pii: 10.1038/s41598-024-51794-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1291Informations de copyright
© 2024. The Author(s).
Références
Nakeeb, A. et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann. Surg. 224, 463–473 (1996) (discussion 473-465).
doi: 10.1097/00000658-199610000-00005
pubmed: 8857851
pmcid: 1235406
Blechacz, B. & Gores, G. J. Cholangiocarcinoma: Advances in pathogenesis, diagnosis, and treatment. Hepatology 48, 308–321. https://doi.org/10.1002/hep.22310 (2008).
doi: 10.1002/hep.22310
pubmed: 18536057
Rizvi, S., Khan, S. A., Hallemeier, C. L., Kelley, R. K. & Gores, G. J. Cholangiocarcinoma: Evolving concepts and therapeutic strategies. Nat. Rev. Clin. Oncol. 15, 95–111. https://doi.org/10.1038/nrclinonc.2017.157 (2018).
doi: 10.1038/nrclinonc.2017.157
pubmed: 28994423
Khan, S. A. et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: An update. Gut 61, 1657–1669. https://doi.org/10.1136/gutjnl-2011-301748 (2012).
doi: 10.1136/gutjnl-2011-301748
pubmed: 22895392
Blechacz, B., Komuta, M., Roskams, T. & Gores, G. J. Clinical diagnosis and staging of cholangiocarcinoma. Nat. Rev. Gastroenterol. Hepatol. 8, 512–522. https://doi.org/10.1038/nrgastro.2011.131 (2011).
doi: 10.1038/nrgastro.2011.131
pubmed: 21808282
pmcid: 3331791
Razumilava, N. & Gores, G. J. Cholangiocarcinoma. Lancet 383, 2168–2179. https://doi.org/10.1016/S0140-6736(13)61903-0 (2014).
doi: 10.1016/S0140-6736(13)61903-0
pubmed: 24581682
pmcid: 4069226
Sripa, B. & Pairojkul, C. Cholangiocarcinoma: Lessons from Thailand. Curr. Opin. Gastroenterol. 24, 349–356. https://doi.org/10.1097/MOG.0b013e3282fbf9b3 (2008).
doi: 10.1097/MOG.0b013e3282fbf9b3
pubmed: 18408464
pmcid: 4130346
Saengboonmee, C., Sawanyawisuth, K., Chamgramol, Y. & Wongkham, S. Prognostic biomarkers for cholangiocarcinoma and their clinical implications. Expert Rev. Anticancer Ther. 18, 579–592. https://doi.org/10.1080/14737140.2018.1467760 (2018).
doi: 10.1080/14737140.2018.1467760
pubmed: 29676221
Suwannatrai, A. T. et al. Bayesian spatial analysis of cholangiocarcinoma in Northeast Thailand. Sci. Rep. 9, 14263. https://doi.org/10.1038/s41598-019-50476-7 (2019).
doi: 10.1038/s41598-019-50476-7
pubmed: 31582774
pmcid: 6776517
Torre, L. A., Siegel, R. L., Islami, F., Bray, F. & Jemal, A. Worldwide burden of and trends in mortality from gallbladder and other biliary tract cancers. Clin. Gastroenterol. Hepatol. 16, 427–437. https://doi.org/10.1016/j.cgh.2017.08.017 (2018).
doi: 10.1016/j.cgh.2017.08.017
pubmed: 28826679
Banales, J. M. et al. Expert consensus document: Cholangiocarcinoma: Current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat. Rev. Gastroenterol. Hepatol. 13, 261–280. https://doi.org/10.1038/nrgastro.2016.51 (2016).
doi: 10.1038/nrgastro.2016.51
pubmed: 27095655
Zhao, D. Y. & Lim, K. H. Current biologics for treatment of biliary tract cancers. J. Gastrointest. Oncol. 8, 430–440. https://doi.org/10.21037/jgo.2017.05.04 (2017).
doi: 10.21037/jgo.2017.05.04
pubmed: 28736630
pmcid: 5506280
Chun, Y. S. & Javle, M. Systemic and adjuvant therapies for intrahepatic cholangiocarcinoma. Cancer Control 24, 1073274817729241. https://doi.org/10.1177/1073274817729241 (2017).
doi: 10.1177/1073274817729241
pubmed: 28975832
pmcid: 5937242
Li, H., Qu, L., Zhang, H., Liu, J. & Zhang, X. A comprehensive transcriptomic landscape of cholangiocarcinoma based on bioinformatics analysis from large cohort of patients. Sci. Rep. 11, 13713. https://doi.org/10.1038/s41598-021-93250-4 (2021).
doi: 10.1038/s41598-021-93250-4
pubmed: 34211100
pmcid: 8249535
Moeini, A., Sia, D., Bardeesy, N., Mazzaferro, V. & Llovet, J. M. Molecular pathogenesis and targeted therapies for intrahepatic cholangiocarcinoma. Clin. Cancer Res. 22, 291–300. https://doi.org/10.1158/1078-0432.CCR-14-3296 (2016).
doi: 10.1158/1078-0432.CCR-14-3296
pubmed: 26405193
Chai, Y. Immunotherapy of biliary tract cancer. Tumour Biol. 37, 2817–2821. https://doi.org/10.1007/s13277-015-4743-x (2016).
doi: 10.1007/s13277-015-4743-x
pubmed: 26729196
Takahashi, R. et al. Current status of immunotherapy for the treatment of biliary tract cancer. Hum. Vaccin. Immunother. 9, 1069–1072. https://doi.org/10.4161/hv.23844 (2013).
doi: 10.4161/hv.23844
pubmed: 23376808
pmcid: 3899141
Blair, A. B. & Murphy, A. Immunotherapy as a treatment for biliary tract cancers: A review of approaches with an eye to the future. Curr. Probl. Cancer https://doi.org/10.1016/j.currproblcancer.2017.10.004 (2017).
doi: 10.1016/j.currproblcancer.2017.10.004
pubmed: 29501212
pmcid: 6178815
Yuan, Z. G., Zeng, T. M. & Tao, C. J. Current and emerging immunotherapeutic approaches for biliary tract cancers. Hepatobiliary Pancreat. Dis. Int. 21, 440–449. https://doi.org/10.1016/j.hbpd.2022.08.015 (2022).
doi: 10.1016/j.hbpd.2022.08.015
pubmed: 36115807
Shimizu, K. et al. Clinical utilization of postoperative dendritic cell vaccine plus activated T-cell transfer in patients with intrahepatic cholangiocarcinoma. J. Hepatobiliary Pancreat. Sci. 19, 171–178. https://doi.org/10.1007/s00534-011-0437-y (2012).
doi: 10.1007/s00534-011-0437-y
pubmed: 21874278
Kan, N., Yoshikawa, K., Matsushita, N. & Fujii, T. The case of a patient with peritoneal metastasis from cholangiocarcinoma who responded to adoptive immunotherapy and cetuximab. Gan To Kagaku Ryoho 40, 1759–1761 (2013).
pubmed: 24393913
Carding, S. R. & Egan, P. J. Gammadelta T cells: Functional plasticity and heterogeneity. Nat. Rev. Immunol. 2, 336–345. https://doi.org/10.1038/nri797 (2002).
doi: 10.1038/nri797
pubmed: 12033739
Kabelitz, D., Wesch, D., Pitters, E. & Zoller, M. Potential of human gamma delta T lymphocytes for immunotherapy of cancer. Int. J. Cancer 112, 727–732. https://doi.org/10.1002/ijc.20445 (2004).
doi: 10.1002/ijc.20445
pubmed: 15386388
Gogoi, D. & Chiplunkar, S. V. Targeting gamma delta T cells for cancer immunotherapy: Bench to bedside. Indian J. Med. Res. 138, 755–761 (2013).
pubmed: 24434328
pmcid: 3928706
Wu, Y. L. et al. Gamma delta T cells and their potential for immunotherapy. Int. J. Biol. Sci. 10, 119–148. https://doi.org/10.7150/ijbs.7823 (2014).
doi: 10.7150/ijbs.7823
pubmed: 24520210
pmcid: 3920167
Fournie, J. J. et al. What lessons can be learned from gamma delta T cell-based cancer immunotherapy trials?. Cell. Mol. Immunol. 10, 35–41. https://doi.org/10.1038/cmi.2012.39 (2013).
doi: 10.1038/cmi.2012.39
pubmed: 23241899
Kobayashi, H. & Tanaka, Y. gammadelta T cell immunotherapy: A review. Pharmaceuticals (Basel) 8, 40–61. https://doi.org/10.3390/ph8010040 (2015).
doi: 10.3390/ph8010040
pubmed: 25686210
Sawaisorn, P. et al. Antigen-presenting cell characteristics of human gammadelta T lymphocytes in chronic myeloid leukemia. Immunol. Investig. 48, 11–26. https://doi.org/10.1080/08820139.2018.1529039 (2019).
doi: 10.1080/08820139.2018.1529039
Lamb, L. S. et al. A combined treatment regimen of MGMT-modified gammadelta T cells and temozolomide chemotherapy is effective against primary high grade gliomas. Sci. Rep. 11, 21133. https://doi.org/10.1038/s41598-021-00536-8 (2021).
doi: 10.1038/s41598-021-00536-8
pubmed: 34702850
pmcid: 8548550
Alnaggar, M. et al. Allogenic Vgamma9Vdelta2 T cell as new potential immunotherapy drug for solid tumor: A case study for cholangiocarcinoma. J. Immunother. Cancer 7, 36. https://doi.org/10.1186/s40425-019-0501-8 (2019).
doi: 10.1186/s40425-019-0501-8
pubmed: 30736852
pmcid: 6368763
Deniger, D. C., Moyes, J. S. & Cooper, L. J. Clinical applications of gamma delta T cells with multivalent immunity. Front. Immunol. 5, 636. https://doi.org/10.3389/fimmu.2014.00636 (2014).
doi: 10.3389/fimmu.2014.00636
pubmed: 25566249
pmcid: 4263175
Forget, M. A. et al. Activation and propagation of tumor-infiltrating lymphocytes on clinical-grade designer artificial antigen-presenting cells for adoptive immunotherapy of melanoma. J. Immunother. 37, 448–460. https://doi.org/10.1097/CJI.0000000000000056 (2014).
doi: 10.1097/CJI.0000000000000056
pubmed: 25304728
pmcid: 4199393
Tanaka, Y. et al. Nonpeptide ligands for human gamma delta T cells. Proc. Natl. Acad. Sci. USA 91, 8175–8179 (1994).
doi: 10.1073/pnas.91.17.8175
pubmed: 8058775
pmcid: 44568
Zhang, Y. et al. Structural studies of Vgamma2Vdelta2 T cell phosphoantigens. Chem. Biol. 13, 985–992. https://doi.org/10.1016/j.chembiol.2006.08.007 (2006).
doi: 10.1016/j.chembiol.2006.08.007
pubmed: 16984888
Thompson, K. & Rogers, M. J. Statins prevent bisphosphonate-induced gamma, delta-T-cell proliferation and activation in vitro. J. Bone Miner. Res. 19, 278–288. https://doi.org/10.1359/JBMR.0301230 (2004).
doi: 10.1359/JBMR.0301230
pubmed: 14969398
Roelofs, A. J. et al. Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. Br. J. Haematol. 144, 245–250. https://doi.org/10.1111/j.1365-2141.2008.07435.x (2009).
doi: 10.1111/j.1365-2141.2008.07435.x
pubmed: 19016713
pmcid: 2659391
Tanaka, Y. et al. Anti-tumor activity and immunotherapeutic potential of a bisphosphonate prodrug. Sci. Rep. 7, 5987. https://doi.org/10.1038/s41598-017-05553-0 (2017).
doi: 10.1038/s41598-017-05553-0
pubmed: 28729550
pmcid: 5519590
Nicol, A. J. et al. Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours. Br. J. Cancer 105, 778–786. https://doi.org/10.1038/bjc.2011.293 (2011).
doi: 10.1038/bjc.2011.293
pubmed: 21847128
pmcid: 3171009
Kang, N. et al. Identification and characterization of Foxp3(+) gammadelta T cells in mouse and human. Immunol. Lett. 125, 105–113. https://doi.org/10.1016/j.imlet.2009.06.005 (2009).
doi: 10.1016/j.imlet.2009.06.005
pubmed: 19539651
Tauriainen, J. et al. Single-cell characterization of in vitro migration and interaction dynamics of T cells expanded with IL-2 and IL-7. Front. Immunol. 6, 196. https://doi.org/10.3389/fimmu.2015.00196 (2015).
doi: 10.3389/fimmu.2015.00196
pubmed: 25972868
pmcid: 4412128
Benczik, M. & Gaffen, S. L. The interleukin (IL)-2 family cytokines: Survival and proliferation signaling pathways in T lymphocytes. Immunol. Investig. 33, 109–142 (2004).
doi: 10.1081/IMM-120030732
Hunter, R. et al. B-cell acute lymphoblastic leukemia promotes an immune suppressive microenvironment that can be overcome by IL-12. Sci. Rep. 12, 11870. https://doi.org/10.1038/s41598-022-16152-z (2022).
doi: 10.1038/s41598-022-16152-z
pubmed: 35831470
pmcid: 9279427
Wesch, D. et al. Direct costimulatory effect of TLR3 ligand poly(I:C) on human gamma delta T lymphocytes. J. Immunol. 176, 1348–1354 (2006).
doi: 10.4049/jimmunol.176.3.1348
pubmed: 16424161
Ring, A. M. et al. Mechanistic and structural insight into the functional dichotomy between IL-2 and IL-15. Nat. Immunol. 13, 1187. https://doi.org/10.1038/ni.2449 (2012).
doi: 10.1038/ni.2449
pubmed: 23104097
pmcid: 3501574
Van Acker, H. H. et al. Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells. J. Hematol. Oncol. 9, 101. https://doi.org/10.1186/s13045-016-0329-3 (2016).
doi: 10.1186/s13045-016-0329-3
pubmed: 27686372
pmcid: 5041439
Okazawa, A. et al. Human intestinal epithelial cell-derived interleukin (IL)-18, along with IL-2, IL-7 and IL-15, is a potent synergistic factor for the proliferation of intraepithelial lymphocytes. Clin. Exp. Immunol. 136, 269–276. https://doi.org/10.1111/j.1365-2249.2004.02431.x (2004).
doi: 10.1111/j.1365-2249.2004.02431.x
pubmed: 15086390
pmcid: 1809038
Montufar-Solis, D., Wang, H. C. & Klein, J. R. Stimulatory and costimulatory effects of IL-18 directed to different small intestinal CD43 T cell subsets. J. Leukoc. Biol. 82, 1166–1173. https://doi.org/10.1189/jlb.0207108 (2007).
doi: 10.1189/jlb.0207108
pubmed: 17702824
Nagamine, I., Yamaguchi, Y., Ohara, M., Ikeda, T. & Okada, M. Induction of gamma delta T cells using zoledronate plus interleukin-2 in patients with metastatic cancer. Hiroshima J. Med. Sci. 58, 37–44 (2009).
pubmed: 19400555
Berglund, S., Gaballa, A., Sawaisorn, P., Sundberg, B. & Uhlin, M. Expansion of gammadelta T cells from cord blood: A therapeutical possibility. Stem Cells Int. 2018, 8529104. https://doi.org/10.1155/2018/8529104 (2018).
doi: 10.1155/2018/8529104
pubmed: 29707004
pmcid: 5863314
Placido, R. et al. Characterization of the immune response of human cord-blood derived gamma/delta T cells to stimulation with aminobisphosphonate compounds. Int. J. Immunopathol. Pharmacol. 24, 101–110. https://doi.org/10.1177/039463201102400112 (2011).
doi: 10.1177/039463201102400112
pubmed: 21496392
Sato, K. et al. Cytotoxic effects of gamma delta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy. Int. J. Cancer 116, 94–99. https://doi.org/10.1002/ijc.20987 (2005).
doi: 10.1002/ijc.20987
pubmed: 15756684
D’Asaro, M. et al. V gamma 9V delta 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells. J. Immunol. 184, 3260–3268. https://doi.org/10.4049/jimmunol.0903454 (2010).
doi: 10.4049/jimmunol.0903454
pubmed: 20154204
Gao, Y. et al. Gamma delta T cells provide an early source of interferon gamma in tumor immunity. J. Exp. Med. 198, 433–442. https://doi.org/10.1084/jem.20030584 (2003).
doi: 10.1084/jem.20030584
pubmed: 12900519
pmcid: 2194096
Groh, V. et al. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc. Natl. Acad. Sci. USA 96, 6879–6884 (1999).
doi: 10.1073/pnas.96.12.6879
pubmed: 10359807
pmcid: 22010
Viey, E. et al. Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma. J. Immunol. 174, 1338–1347 (2005).
doi: 10.4049/jimmunol.174.3.1338
pubmed: 15661891
Kabelitz, D. Human gammadelta T cells: From a neglected lymphocyte population to cellular immunotherapy: A personal reflection of 30years of gammadelta T cell research. Clin. Immunol. 172, 90–97. https://doi.org/10.1016/j.clim.2016.07.012 (2016).
doi: 10.1016/j.clim.2016.07.012
pubmed: 27444042
Betts, M. R. et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J. Immunol. Methods 281, 65–78 (2003).
doi: 10.1016/S0022-1759(03)00265-5
pubmed: 14580882
Betts, M. R. & Koup, R. A. Detection of T-cell degranulation: CD107a and b. Methods Cell Biol. 75, 497–512 (2004).
doi: 10.1016/S0091-679X(04)75020-7
pubmed: 15603439
Cheng, X. T. et al. Revisiting LAMP1 as a marker for degradative autophagy-lysosomal organelles in the nervous system. Autophagy 14, 1472–1474. https://doi.org/10.1080/15548627.2018.1482147 (2018).
doi: 10.1080/15548627.2018.1482147
pubmed: 29940787
pmcid: 6103665
Braza, M. S., Klein, B., Fiol, G. & Rossi, J. F. gammadelta T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody. Haematologica 96, 400–407. https://doi.org/10.3324/haematol.2010.029520 (2011).
doi: 10.3324/haematol.2010.029520
pubmed: 21109686
Marks, E. I. & Yee, N. S. Immunotherapeutic approaches in biliary tract carcinoma: Current status and emerging strategies. World J. Gastrointest. Oncol. 7, 338–346. https://doi.org/10.4251/wjgo.v7.i11.338 (2015).
doi: 10.4251/wjgo.v7.i11.338
pubmed: 26600933
pmcid: 4644856
Okusaka, T., Ueno, M., Sato, T. & Heike, Y. Possibility of immunotherapy for biliary tract cancer: how do we prove efficacy? Introduction to a current ongoing phase I and randomized phase II study to evaluate the efficacy and safety of adding Wilms tumor 1 peptide vaccine to gemcitabine and cisplatin for the treatment of advanced biliary tract cancer (WT-BT trial). J. Hepatobiliary Pancreat. Sci. 19, 314–318. https://doi.org/10.1007/s00534-011-0495-1 (2012).
doi: 10.1007/s00534-011-0495-1
pubmed: 22273718
Lertworapreecha, M., Patumraj, S., Niruthisard, S., Hansasuta, P. & Bhattarakosol, P. Cytotoxic function of gamma delta (gamma/delta) T cells against pamidronate-treated cervical cancer cells. Indian J. Exp. Biol. 51, 597–605 (2013).
pubmed: 24228383